Navigation Links
Publication of Shire plc's Annual Report 2008
Date:3/25/2009

hares control over the planning and execution of product development with collaborative partners. The Group cannot be certain that, if clinical trials are completed, either the Group or its collaborative partners will file for, or receive, required authorizations to manufacture and/or market potential products (including a marketing authorization application or Abbreviated New Drug applications ('ANDA')) or that such application will be reviewed and approved by the regulatory authorities in a timely manner, if at all.

If the Group is unable to meet the requirements of regulators in relation to a particular product, it may be unable to develop the product or obtain or retain the necessary marketing approvals

Drug companies are required to obtain regulatory approval before manufacturing and marketing most drug products. Regulatory approval is generally based on the results of:

    - quality testing (chemistry, manufacturing and controls);

    - non-clinical testing; and

    - clinical testing.

The clinical development, manufacture, marketing and sale of pharmaceutical products is subject to extensive regulation, including separate regulation by each member state of the European Union ('EU'), the European Medicines Agency ('EMEA') itself and federal, state and local regulation in the US. Unanticipated legislative and other regulatory actions and developments concerning various aspects of the Group's operations and products may restrict its ability to sell one or more of its products or to sell those products at a profit. The generation of data is regulated and any generated data is susceptible to varying interpretations that could delay, limit or prevent regulatory approval. Required regulatory approvals may not be obtained in a timely manner, if at all. In addition, other regulatory requirements for any such proposed products may not be met.

Even if the Group obtains r
'/>"/>

SOURCE Shire Plc
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33

Related biology technology :

1. Bionovo Announces Publication of Positive Phase 2 Trial Results for Menerba(TM)
2. Sopherion Therapeutics, LLC Announces Publication of Phase I/II Myocet(R) (Nonpegylated Liposomal Doxorubicin) Data in Advanced Breast Cancer Patients
3. InVitria Among Leading Innovators in Cell Culture Media According to Top Biotechnology Publication
4. BioTrends Releases TreatmentTrends(TM): US Nephrology, an Ongoing Syndicated Publication Providing Insight into Physician Perceptions and Management of Renal Anemia, Hyperphosphatemia, and Secondary Hyperparathyroidism
5. New Publications Show Noninvasive Magnetic Resonance-Guided Focused Ultrasound to be a Potentially Safe, Effective Pain-Relieving Treatment for Bone Metastases
6. PharmSource and BioProcess Technology Consultants Announce Publication of New Market Report: Cell Culture Manufacturing Capacity: Trends and Outlook through 2013
7. Webcast Alert: Regulus Therapeutics, Alnylam Pharmaceuticals and Isis Pharmaceuticals Announce New Nature Publication on miR-21 Conference Call
8. Genomic Health Announces Publication of a Study Demonstrating the Oncotype DX(R) Breast Cancer Assay Influences Chemotherapy Treatment Recommendation in 44 Percent of Patients Evaluated
9. Publication on Tregitopes in Blood Journal of October 2008
10. Repligen Announces Publication of Positive Results with Proprietary HDAC Inhibitor in Huntingtons Disease Model
11. ABMAC Foundation Announces Publication of an Historic Volume Documenting the Creation of a National Health Care System in Taiwan
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... Louis, Missouri (PRWEB) December 23, 2014 GMO ... biotechnology company, Syngenta, are in the process of being consolidated ... case is In Re: Syngenta AG MIR 162 Corn Litigation, ... District of Kansas. , Management of the Syngenta GMO corn ...
(Date:12/24/2014)... SoundConnect’s 2015 next ... edge communication technology, provide continued education and inform ... series demonstrates online communication features and benefits; empowering ... most innovative and powerful tools. , According to ...
(Date:12/24/2014)... (PRWEB) December 23, 2014 According to Ross ... Island Affiliate of ITRA Global, the national office market continues ... recovery. This is evidenced by the third quarter’s surprising ... market. Low energy costs have held inflation down and ...
(Date:12/24/2014)... Nashville Fertility Center announced that Dr. ... Society for Reproductive Medicine (ASRM), a leading professional organization committed ... his new role as treasurer, Dr. Hill also fills a ... in furthering the mission of ASRM. , Dr. Hill ...
Breaking Biology Technology:Carey Danis & Lowe Reports on Syngenta GMO Corn Transfer Order 2SoundConnect Launches Leading Edge Business Communications Webinar Series 2SoundConnect Launches Leading Edge Business Communications Webinar Series 3ITRA Global Reports Long Island Is Out of Sync With The National Office Market 2ITRA Global Reports Long Island Is Out of Sync With The National Office Market 3Nashville Fertility Center Announces Dr. George A. Hill Selected to Serve as ASRM Treasurer for 2014-15 2Nashville Fertility Center Announces Dr. George A. Hill Selected to Serve as ASRM Treasurer for 2014-15 3
... - Biomira Inc. (Nasdaq: BIOM ),(TSX: BRA) ... a randomized Phase II trial of the Stimuvax(R) ... results suggest that Stimuvax,combined with best supportive care ... stage IIIB NSCLC who had either responded or ...
... Calif., Sept. 5 Hyperion,Therapeutics, a biopharmaceutical company ... hepatology therapies for the,treatment of Urea Cycle Disorders ... million Series B financing. Leading the round was,Sofinnova ... and,NEA, all of Menlo Park, CA. WRF Capital ...
... 5 Arena Pharmaceuticals,Inc. (Nasdaq: ARNA ) announced ... Bear Stearns 20th Annual Healthcare Conference on September,11, 2007 ... at the Grand,Hyatt Hotel in New York City. Jack ... provide a corporate overview of the,company and its clinical ...
Cached Biology Technology:Stimuvax(R) Phase II data highlight three-year survival results for patients with non-small cell lung cancer 2Stimuvax(R) Phase II data highlight three-year survival results for patients with non-small cell lung cancer 3Stimuvax(R) Phase II data highlight three-year survival results for patients with non-small cell lung cancer 4Hyperion Therapeutics Secures $40 Million In Series B Round 2Arena Pharmaceuticals to Present at the Bear Stearns 20th Annual Healthcare Conference 2Arena Pharmaceuticals to Present at the Bear Stearns 20th Annual Healthcare Conference 3
(Date:12/22/2014)... 2014 Holiday Season may be the brightest ever for ... the long anticipated floodgates for consumer biometrics may finally ... phones, tablets, and wearable mobile devices that incorporate biometrics ... with nearly 4.8 billion biometric devices by 2020.   ...
(Date:12/19/2014)... 18, 2014   LaunchKey , the first decentralized mobile ... Internet of Things era, today announced the close of ... was led by Metamorphic Ventures with participation from ENIAC ... and others.  LaunchKey has raised $4 million to date, ...
(Date:12/17/2014)... Valencell, a leader in performance biometric data sensor ... leaders such as Intel, Jabra, Atlas, and Scosche to ... These products will be showcased at CES 2015, taking ... . "Our partners choose PerformTek biometrics, ...
Breaking Biology News(10 mins):First Season of Holiday Shopping with Mobile Biometric Payments Wraps Up With a Present for Biometrics Industry: A Rosy Forecast for More Than 2 Billion Users of 4.8 Billion Mobile Biometric Devices by 2020 2LaunchKey Raises $3 Million in Additional Funding Led by Metamorphic Ventures 2LaunchKey Raises $3 Million in Additional Funding Led by Metamorphic Ventures 3Valencell PerformTek Biometrics Power the Most Accurate Wearables at CES 2015 2
... starfish to carry out one of the most remarkable forms ... by first extending its stomach out of its mouth and ... and clams. The prey tissue is partially digested externally before ... digestive glands. , The researchers at Queen Mary, University of ...
... article published in this month,s issue of Pediatrics ... Medicine (BUSM) stress the importance of physicians recognizing that ... to make accurate health assessments for both mother and ... guidelines set a standardized risk assessment of herbal supplement ...
... will present the Society,s highest honor, the 2013 Wallace ... Professor Sir David Weatherall, MD, of the University of ... combining seminal discoveries, visionary translational research leadership, and a ... improve clinical care for thousands throughout the developing world. ...
Cached Biology News:Scientists uncover secrets of starfish's bizarre feeding mechanism 2Study finds physicians need to better recognize use of herbal supplements while breastfeeding 2Professor Sir David Weatherall, M.D., recieves 2013 Wallace H. Coulter Award 2Professor Sir David Weatherall, M.D., recieves 2013 Wallace H. Coulter Award 3Professor Sir David Weatherall, M.D., recieves 2013 Wallace H. Coulter Award 4
Mouse Iduronate 2-Sulfatase Affinity Purified Polyclonal Ab Keywords: Sulfatases, Iduronate 2-Sulfatase, Mucopolysaccharidosis, Hunter Syndrome, Glycobiology Protein Family: Proteoglycan Regu...
Request Info...
Mouse Limitin MAb (Clone 183727)...
Normal human serum collected off the clot from healthy normal humans. Each donor unit is negative for anti-HIV 1&2, HIV-Ag, HCV, and HBsAg by FDA required tests...
Biology Products: